Thanks Ohm. Your comment about the lower SOC in Brazil makes a lot of sense. On the flip side (you know me), would that make FDA a little queasy about any comparisons that we might provide? It would be interesting as to how they would view that.

Do you agree with me that NP did not put much emphasis on the Severe trial in the call today? In fact, you made a much stronger case for this trial in four sentences than I heard from the company today in 10 minutes of Brazil discussion.